Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IP6K1 | Q92551 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | MAPT | P10636 | 4/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA7 | P43166 | 1/20 | 0.44 |
| ▸ | XDH | P47989 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.44 |
| ▸ | AURKA | O14965 | 1/20 | 0.43 |
| ▸ | RAF1 | P04049 | 1/20 | 0.43 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.43 |
| ▸ | KIF11 | P52732 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 4/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29041890 | 0.83 | PGR (0.51) | IP6K1ALDH1A1LMNAMAPTCA12 | |
| SCHEMBL30459975 | 0.83 | PGR (0.51) | IP6K1ALDH1A1LMNAMAPTCA12 | |
| SCHEMBL12548325 | 0.77 | IP6K1 (0.57) | IP6K1ALDH1A1LMNA | |
| SCHEMBL22711811 | 0.76 | IP6K1 (0.56) | IP6K1ALDH1A1LMNAMAPTHPGD | |
| SCHEMBL12548174 | 0.76 | IP6K1 (0.56) | IP6K1ALDH1A1LMNA | |
| SCHEMBL3478652 | 0.75 | MAPK1 (0.52) | IP6K1ALDH1A1LMNAMAPTCA12 | |
| Hydrochloric Acid SCHEMBL1949327 | 0.75 | IP6K1 (0.55) | IP6K1ALDH1A1LMNA | |
| SCHEMBL30681107 | 0.74 | IP6K1 (0.62) | IP6K1 | |
| SCHEMBL29930681 | 0.74 | IP6K1 (0.62) | IP6K1 | |
| SCHEMBL29825095 | 0.74 | MAPK14 (0.53) | ALDH1A1LMNAMAPTCA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8987474-B2 | Inhibition of Shp2/PTPN11 protein tyrosine phosphatase by NSC-87877, NSC-117199 and their analogs | UNIVERSITY OF SOUTH FLORIDA (US) | 2015-03-24 | — | — | US | disclosed |
| US-8987474-B2 | Inhibition of Shp2/PTPN11 protein tyrosine phosphatase by NSC-87877, NSC-117199 and their analogs | UNIVERSITY OF SOUTH FLORIDA (US) | 2015-03-24 | — | — | US | disclosed |
| US-8987474-B2 | Inhibition of Shp2/PTPN11 protein tyrosine phosphatase by NSC-87877, NSC-117199 and their analogs | UNIVERSITY OF SOUTH FLORIDA (US) | 2015-03-24 | — | — | US | disclosed |
| WO-2009135000-A2 | INHIBITION OF SHP2/PTPN11 PROTEIN TYROSINE PHOSPHATASE BY NSC-117199 AND ANALOGS | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2009-11-05 | — | — | WO | disclosed |
| US-20080176309-A1 | 8-hydroxy-7-(6-sulfonaphthalen-2-yl)diazenyl-quinoline-5-sulfonic acid (NSC-87877); Src homology-2 domains; Noonan syndrome, cancer | UNIVERSITY OF SOUTH FLORIDA (US) | 2008-07-24 | — | — | US | disclosed |
| US-20080176309-A1 | 8-hydroxy-7-(6-sulfonaphthalen-2-yl)diazenyl-quinoline-5-sulfonic acid (NSC-87877); Src homology-2 domains; Noonan syndrome, cancer | UNIVERSITY OF SOUTH FLORIDA (US) | 2008-07-24 | — | — | US | disclosed |
| US-20080176309-A1 | 8-hydroxy-7-(6-sulfonaphthalen-2-yl)diazenyl-quinoline-5-sulfonic acid (NSC-87877); Src homology-2 domains; Noonan syndrome, cancer | UNIVERSITY OF SOUTH FLORIDA (US) | 2008-07-24 | — | — | US | disclosed |
| WO-2007117699-A2 | INHIBITION OF SHP2/PTPN11 PROTEIN TYROSINE PHOSPHATASE BY NSC-87877, NSC-117199 AND THEIR ANALOGS | UNIVERSITY OF SOUTH FLORIDA (US) | 2007-10-18 | — | — | WO | disclosed |
| WO-2007117699-A2 | INHIBITION OF SHP2/PTPN11 PROTEIN TYROSINE PHOSPHATASE BY NSC-87877, NSC-117199 AND THEIR ANALOGS | UNIVERSITY OF SOUTH FLORIDA (US) | 2007-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176309-A1 | 8-hydroxy-7-(6-sulfonaphthalen-2-yl)diazenyl-quinoline-5-sulfonic acid (NSC-87877); Src homology-2 domains; Noonan syndrome, cancer | PTPN7, PTPN1, PTPN2 | IP6K1 582/4885ALDH1A1 3859/4885LMNA 4809/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.